Clinical trials shows MAST as a Phase 1, so my guess is Yuman has either misspoken, or is simply referring to it as a Phase 2 because its moved to an expansion cohort for a specific indication (cholangio), where MAST started in Phase 1 as a 'basket' study for multiple cancer types. I wouldn't read too much into that.
Media Thread, page-15684
-
- There are more pages in this discussion • 322 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.5¢ |
Change
-0.002(4.26%) |
Mkt cap ! $334.7M | |||
| Open | High | Low | Value | Volume |
| 4.7¢ | 4.8¢ | 4.4¢ | $890.8K | 19.42M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 176601 | 4.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.6¢ | 877572 | 7 |
View Market Depth
| Last trade - 16.10pm 06/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |